{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:26:59Z","timestamp":1758814019752,"version":"3.37.3"},"reference-count":41,"publisher":"Portland Press Ltd.","issue":"17","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Human serine protease inhibitors (serpins) are the main inhibitors of serine proteases, but some of them also have the capability to effectively inhibit cysteine proteases. Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) main protease (Mpro) is a chymotrypsin-type cysteine protease that is needed to produce functional proteins essential for virus replication and transcription. Serpin traps its target proteases by presenting a reactive center loop (RCL) as protease-specific cleavage site, resulting in protease inactivation. Mpro target sites with its active site serine and other flanking residues can possibly interact with serpins. Alternatively, RCL cleavage site of serpins with known evidence of inhibition of cysteine proteases can be replaced by Mpro target site to make chimeric proteins. Purified chimeric serpin can possibly inhibit Mpro that can be assessed indirectly by observing the decrease in ability of Mpro to cleave its chromogenic substrate. Chimeric serpins with best interaction and active site binding and with ability to form 1:1 serpin\u2013Mpro complex in human plasma can be assessed by using SDS\/PAGE and Western blot analysis with serpin antibody. Trapping SARS-CoV-2 Mpro cysteine protease using cross-class serpin cysteine protease inhibition activity is a novel idea with significant therapeutic potential.<\/jats:p>","DOI":"10.1042\/cs20200767","type":"journal-article","created":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T08:38:26Z","timestamp":1598949506000},"page":"2235-2241","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Using serpins cysteine protease cross-specificity to possibly trap SARS-CoV-2 Mpro with reactive center loop chimera"],"prefix":"10.1042","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9888-2213","authenticated-orcid":false,"given":"Mohamad\u00a0Aman","family":"Jairajpuri","sequence":"first","affiliation":[{"name":"Department of Biosciences, Jamia Millia Islamia, New Delhi 110025, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoyab","family":"Ansari","sequence":"additional","affiliation":[{"name":"Department of Biosciences, Jamia Millia Islamia, New Delhi 110025, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"2021113011153954700_B1","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus Main Proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"2021113011153954700_B2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ketoamide inhibitors","volume":"24","author":"Zhang","year":"2020","journal-title":"Science"},{"volume-title":"Serpins: Structure, Function and Biology","year":"1996","author":"Gettins","key":"2021113011153954700_B3"},{"key":"2021113011153954700_B4","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.1021\/bi0159985","article-title":"Evidence that serpin architecture intrinsically supports papain-like cysteine protease inhibition: engineering alpha(1)-antitrypsin to inhibit cathepsin proteases","volume":"41","author":"Irving","year":"2002","journal-title":"Biochemistry"},{"key":"2021113011153954700_B5","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.1021\/cr010170+","article-title":"Serpin structure, mechanism, and function","volume":"102","author":"Gettins","year":"2002","journal-title":"Chem. Rev."},{"key":"2021113011153954700_B6","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/pro.3794","article-title":"Engineering the serpin\u03b11-antitrypsin: a diversity of goals and techniques","volume":"29","author":"Scott","year":"2020","journal-title":"Protein Sci."},{"key":"2021113011153954700_B7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from COVID-19 virus and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature."},{"key":"2021113011153954700_B8","doi-asserted-by":"crossref","first-page":"10593","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"2021113011153954700_B9","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","article-title":"SARS-CoV-2 vaccines: status report","volume":"52","author":"Amanat","year":"2020","journal-title":"Immunity"},{"key":"2021113011153954700_B10","doi-asserted-by":"publisher","first-page":"30571","DOI":"10.1016\/j.chest.2020.03.039","article-title":"Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection","volume":"20","author":"Zhang","year":"2020","journal-title":"Chest"},{"key":"2021113011153954700_B11","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.3390\/ijms21093099","article-title":"Structural and evolutionary analysis indicate that the SARS-CoV-2 Mpro is a challenging target for small-molecule inhibitor design","volume":"21","author":"Bz\u00f3wka","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2021113011153954700_B12","doi-asserted-by":"publisher","first-page":"137489","DOI":"10.1016\/j.cplett.2020.137489","article-title":"Identification of potential binders of the main protease 3CLpro of the COVID-19 via structure-based ligand design and molecular modeling","volume":"750","author":"Macchiagodena","year":"2020","journal-title":"Chem. Phys. Lett."},{"key":"2021113011153954700_B13","first-page":"13","article-title":"Computational determination of potential inhibitors of SARS-CoV-2 main protease","volume":"21","author":"Ngo","year":"2020","journal-title":"ChemRxiv"},{"key":"2021113011153954700_B14","first-page":"57","article-title":"In-silico drug repurposing for targeting SARS-CoV-2","volume":"8","author":"Sharma","journal-title":"ChemRxiv"},{"key":"2021113011153954700_B15","doi-asserted-by":"publisher","DOI":"10.1101\/2020.05.29.123190","article-title":"Impact of emerging mutations on the dynamic properties the SARS-CoV-2 main protease: an in silico investigation","author":"Amamuddy","year":"2020","journal-title":"bioRxiv"},{"key":"2021113011153954700_B16","doi-asserted-by":"crossref","first-page":"12997","DOI":"10.1073\/pnas.1601327113","article-title":"SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity","volume":"133","author":"Muramatsu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011153954700_B17","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1128\/JVI.02114-07","article-title":"Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design","volume":"82","author":"Xue","year":"2008","journal-title":"J. Virol."},{"key":"2021113011153954700_B18","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1042\/BCJ20200029","article-title":"Processing of the SARS-CoV pp1a\/ab nsp7\u201310 region","volume":"477","author":"Krichel","year":"2020","journal-title":"Biochem. J."},{"key":"2021113011153954700_B19","doi-asserted-by":"publisher","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J. Med. Chem."},{"key":"2021113011153954700_B20","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1128\/JVI.02114-07","article-title":"(2008) Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design","volume":"82","author":"Xue","journal-title":"J. Virol."},{"key":"2021113011153954700_B21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4161\/pri.1.1.3974","article-title":"Protein misfolding and the serpinopathies","volume":"1","author":"Belorgey","year":"2007","journal-title":"Prion"},{"key":"2021113011153954700_B22","doi-asserted-by":"publisher","first-page":"14683","DOI":"10.1073\/pnas.94.26.14683","article-title":"The anticoagulant activation of antithrombin by heparin","volume":"94","author":"Jin","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011153954700_B23","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/B978-0-12-386471-0.00016-X","article-title":"Human SCCA serpins inhibit staphylococcal cysteine proteases by forming classic \u201cserpin-like\u201d covalent complexes","volume":"499","author":"Kantyka","year":"2011","journal-title":"Methods Enzymol."},{"key":"2021113011153954700_B24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fmed.2019.00025","article-title":"SERPINs\u2014from trap to treatment","volume":"6","author":"Sanrattana","year":"2019","journal-title":"Front. Med."},{"key":"2021113011153954700_B25","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1110\/ps.9.8.1423","article-title":"Crystal structure of viral serpincrmA provides insights into its mechanism of cysteine proteinase inhibition","volume":"9","author":"Simonovic","year":"2000","journal-title":"Protein Sci."},{"key":"2021113011153954700_B26","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1086\/497606","article-title":"The Granzyme B inhibitor SERPINB9 (protease inhibitor 9) circulates in blood and increases on primary cytomegalovirus infection after renal transplantation","volume":"192","author":"Rowshani","year":"2005","journal-title":"J. Infect. Dis."},{"key":"2021113011153954700_B27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1515\/bc.2011.044","article-title":"Inhibition of Staphylococcus aureus cysteine proteases by human serpin potentially limits staphylococcal virulence","volume":"392","author":"Kantyka","year":"2011","journal-title":"Biol. Chem."},{"key":"2021113011153954700_B28","doi-asserted-by":"publisher","first-page":"7293","DOI":"10.1073\/pnas.95.13.7293","article-title":"alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent","volume":"95","author":"Jean","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011153954700_B29","doi-asserted-by":"publisher","first-page":"e0185074","DOI":"10.1371\/journal.pone.0185074","article-title":"Role of the P2 residue of human alpha 1-antitrypsin in determining target protease specificity","volume":"12","author":"Chung","year":"2017","journal-title":"PLoS ONE"},{"key":"2021113011153954700_B30","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1042\/bj3350701","article-title":"Inactivation of papain by antithrombin due to autolytic digestion: a model of serpin inactivation of cysteine proteinases","volume":"335","author":"Bj\u00f6rk","year":"1998","journal-title":"Biochem. J."},{"key":"2021113011153954700_B31","doi-asserted-by":"publisher","first-page":"13424","DOI":"10.1074\/jbc.M600415200","article-title":"Residues Tyr253 and Glu255 in strand 3 of beta-sheet C of antithrombin are key determinants of an exosite made accessible by heparin activation to promote rapid inhibition of factors Xa and IXa","volume":"281","author":"Izaguirre","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2021113011153954700_B32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb. Res."},{"key":"2021113011153954700_B33","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"2021113011153954700_B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06062-x","article-title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study","author":"Helms","year":"2020","journal-title":"Intensive Care Med."},{"key":"2021113011153954700_B35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"185","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"2021113011153954700_B36","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/jth.14810","article-title":"ISTH interim guidance on recognition and management of coagulopathy in COVID-19","volume":"18","author":"Thachil","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"2021113011153954700_B37","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"2021113011153954700_B38","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2021113011153954700_B39","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"2021113011153954700_B40","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1111\/j.1742-4658.2005.04880.x","article-title":"Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans","volume":"272","author":"Pike","year":"2005","journal-title":"FEBS J."},{"key":"2021113011153954700_B41","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00025","article-title":"Serpins: From trap to treatment","volume":"6","author":"Sanrattana","year":"2019","journal-title":"Front. Med."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/17\/2235\/892082\/cs-2020-0767.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/134\/17\/2235\/892082\/cs-2020-0767.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:13:41Z","timestamp":1638274421000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/134\/17\/2235\/226266\/Using-serpins-cysteine-protease-cross-specificity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":41,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,9,18]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20200767","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"type":"print","value":"0143-5221"},{"type":"electronic","value":"1470-8736"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,9,1]]}}}